Chronic treatment of aged Tg2576 mice with a novel agent, described as a dual antagonist of PDE5 and histone deacetylases, reduced cognitive deficits and enhanced dendritic spine density [33]. The gene discussed is PDE5A; the disease is Cognitive impairment.